Cogent Biosciences, Inc..
COGT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead product candidate is bezuclastinib, a selective tyrosine kinase inhibitor designed to address the primary genetic drivers of systemic mastocytosis (SM) a...Show More
Better Health for All
40
Cogent Biosciences is a biotechnology company entirely focused on developing precision therapies for genetically defined diseases, with its lead product candidate, bezuclastinib, targeting systemic mastocytosis and gastrointestinal stromal tumors.
1
This indicates that the company's entire business is devoted to health improvement, aligning with 95-97% of its product portfolio delivering exceptional health benefits. As a biotechnology company whose core business is developing new therapies, 100% of its R&D budget is dedicated to health improvement. The company is conducting clinical trials for bezuclastinib, which means it engages in health research, making the clinical_trial_ethics KPI applicable.
2
Fair Money & Economic Opportunity
0
No evidence available to assess Cogent Biosciences, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
Cogent Biosciences reported a CEO to median employee pay ratio of 19:1 for the 2024 fiscal year, with the CEO's total compensation at $4,917,890 and median employee compensation at $258,662.
1
Employee sentiment is positive, with 88% of employees stating they would recommend working at the company.
2
The overall employee rating is 4.5 out of 5 stars, which is 28% above the industry average for the Pharmaceutical & Biotechnology sector.
3
Fair Trade & Ethical Sourcing
0
No specific, quantitative data regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend was found in the provided articles.
1
While a Supplier Code of Conduct exists, it outlines expectations rather than providing measurable performance data for the specified KPIs.
2
Honest & Fair Business
30
Cogent Biosciences has a controversy level of 0.5.
1
This indicates a very low severity-weighted ESG controversy score, placing it in a high percentile for controversy management. No regulatory actions, violations, fines, or compliance issues are mentioned in the provided articles.
2
Kind to Animals
-50
The company conducts preclinical studies and preclinical characterization, as referenced in publications and financial reports.
1
However, no explicit formal animal testing policy is mentioned across any of the provided articles.
2
No War, No Weapons
0
No evidence was found in the provided articles to assess Cogent Biosciences against any of the KPIs for the 'No War, No Weapons' ethical value. The articles focus on the company's biotechnology operations, clinical trials for cancer therapies, and financial announcements, with no mention of arms manufacturing, military contracts, dual-use technologies, or peacebuilding initiatives.
1
Planet-Friendly Business
0
No specific, quantifiable data points relevant to the Planet-Friendly Business ethical value were found in the provided articles. The articles either explicitly state 'No data provided' for environmental metrics or contain information that is not a quantifiable metric applicable to the company's overall performance against the rubric's KPIs.
1
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Cogent Biosciences' performance on any of the KPIs related to Respect for Cultures & Communities.
1
The articles focus solely on the company's research pipeline and clinical trials, without addressing community engagement, cultural sensitivity, or related social responsibility metrics.
2
Safe & Smart Tech
0
Cogent Biosciences complies with the EU-U.S. Data Privacy Framework, the UK Extension, and the Swiss-U.S. Data Privacy Framework, having certified its adherence to the principles of these frameworks with the U.S. Department of Commerce.
1
The company is subject to the investigatory and enforcement powers of the United States Federal Trade Commission.
2
Its privacy policy, last modified January 26, 2026, states that individuals have rights to access, correct, amend, or delete their personal data, and specific rights including rectification, erasure, restriction of processing, objection, data portability, and to withdraw consent.
3
The company uses AI-enabled tools for regulatory preparation, research, analysis, and operational activities, but these tools are not used to make decisions that produce legal or similarly significant effects for individuals.
4
For decisions that may seriously impact individuals, the company states it will explain when and why this might happen, and its potential effect.
5
The company's Code of Business Conduct and Ethics addresses unauthorized use of company assets and confidential information.
6
Some laws require the company to keep trial records for at least 25 years after conclusion.
7
Zero Waste & Sustainable Products
0
No specific, concrete data points were found across the provided articles for any of the KPIs related to Zero Waste & Sustainable Products.
1
The articles primarily focus on financial performance, clinical trial updates, and general ESG risk ratings without detailing waste management practices, product recyclability, packaging sustainability, or other relevant initiatives.